Cubist Systematic Strategies, LLC Puma Biotechnology, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.29 - $7.4 $225,829 - $389,543	52,641 Added 148.75%	88,029 $466,000
Q4 2023 Feb 14, 2024	SELL	$2.23 - $4.49 $3,409 - $6,865	-1,529 Reduced 4.14%	35,388 $153,000
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $40,041 - $62,270	15,225 Added 70.19%	36,917 $97,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $302,863 - $417,019	-116,486 Reduced 84.3%	21,692 $76,000
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $138,655 - $302,406	62,740 Added 83.17%	138,178 $426,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $108,760 - $260,614	51,302 Added 212.55%	75,438 $319,000
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $103,970 - $175,879	-45,802 Reduced 65.49%	24,136 $57,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $51,056 - $102,735	31,132 Added 80.22%	69,938 $199,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $12,909 - $19,637	-6,061 Reduced 13.51%	38,806 $112,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $37,172 - $85,822	13,043 Added 40.98%	44,867 $136,000
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $138,368 - $195,969	-20,870 Reduced 39.61%	31,824 $223,000
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $292,855 - $378,299	32,612 Added 162.39%	52,694 $484,000
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $188,369 - $273,717	20,082 New	20,082 $195,000
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $191,187 - $224,192	-20,125 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $449,228 - $848,472	-64,084 Reduced 76.1%	20,125 $210,000
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $45,209 - $104,889	7,199 Added 9.35%	84,209 $711,000
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $154,264 - $254,655	23,733 Added 44.55%	77,010 $674,000
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $414,627 - $608,910	-47,386 Reduced 47.07%	53,277 $574,000
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $922,081 - $2.68 Million	74,966 Added 291.73%	100,663 $1.28 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $423,645 - $864,220	20,397 Added 384.85%	25,697 $997,000
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $54,891 - $127,724	-2,735 Reduced 34.04%	5,300 $108,000
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $314,562 - $456,954	7,635 Added 1908.75%	8,035 $368,000
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $33,906 - $47,911	-702 Reduced 63.7%	400 $24,000
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $58,267 - $96,868	-976 Reduced 46.97%	1,102 $75,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $102,108 - $144,105	1,088 Added 109.9%	2,078 $205,000
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $71,280 - $118,552	990	990 $119,000

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

Vanguard Group Inc Valley Forge, PA

3.64M
Shares

$9.85 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.57M
Shares

$9.68 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

3.06M
Shares

$8.3 Million
0.42% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.88M
Shares

$7.81 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.97M
Shares

$5.34 Million
0.02% of portfolio

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $123M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account